Selank Research: The Tuftsin Analogue and Its Published Findings
Selank is a synthetic heptapeptide analogue of tuftsin. What rodent studies report on BDNF, GABA-related genes and anxiety models, and the limits.
Selank is a synthetic seven-amino-acid peptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as an analogue of tuftsin (Thr-Lys-Pro-Arg), a naturally occurring tetrapeptide cleaved from the Fc region of immunoglobulin G, with a C-terminal Pro-Gly-Pro extension added for stability. Like Semax, it has been studied mainly by research groups in Russia. For laboratories, Selank is interesting as a tool peptide for probing neurotrophin signalling, GABAergic gene expression and stress-related behavioural models in rodents. This article covers where the peptide comes from, what the key published studies report and how to read that literature carefully.
Origins: from tuftsin to a stabilized heptapeptide
Tuftsin was identified in the 1970s as a short fragment of IgG with activity in immune-cell models. Short natural peptides of this kind are broken down quickly by peptidases. Selank keeps the tuftsin core (Thr-Lys-Pro-Arg) and adds Pro-Gly-Pro at the C-terminus. The same Pro-Gly-Pro (PGP) motif appears in related research peptides such as Semax. PGP can have activity of its own in some models, so careful experiments separate effects of the full heptapeptide from those of the extension alone. Selank is a synthetic tuftsin analogue engineered for greater persistence in biological systems, not native tuftsin itself.
Key published research
BDNF expression after intranasal administration in rats
One of the clearer mechanistic papers is Inozemtseva and colleagues, published in Doklady Biological Sciences in 2008. The authors administered Selank intranasally to rats and measured brain-derived neurotrophic factor (BDNF) expression in the hippocampus in vivo.
They reported that the peptide regulated hippocampal BDNF expression under the conditions of their study. The work sits in the same neurotrophin-focused tradition as related ACTH-fragment analogue research: a behavioural or physiological intervention is paired with a molecular readout in a defined brain region. Limits are the usual ones for this literature: a single species, defined time points and a concentrated set of laboratories.
BDNF content, ethanol-related memory impairment and cortex vs hippocampus
Kolik and colleagues (2019) in Bulletin of Experimental Biology and Medicine examined Selank in a rat model of ethanol-induced memory impairment. They reported that the peptide protected against that impairment and linked the effect to regulation of BDNF content in both the hippocampus and the prefrontal cortex.
This paper is useful because it measures BDNF protein content in two regions rather than relying only on transcription, and because it ties a molecular change to a behavioural endpoint in the same animals. It remains a rodent pharmacology study: it does not establish effects outside that model system.
Gene expression in GABAergic neurotransmission
Volkova and colleagues (2016) in Frontiers in Pharmacology reported that Selank administration affected the expression of some genes involved in GABAergic neurotransmission. GABA is the main inhibitory neurotransmitter in the mammalian central nervous system, so changes in related transcripts matter for anxiety and stress models. As with other gene-expression studies, mRNA changes are not the same as changes in protein levels or behaviour. Vyunova and colleagues' 2018 review in Protein & Peptide Letters maps proposed molecular aspects of the heptapeptide's reported activity; like much of this literature, it draws on a relatively small research community.
Interaction with diazepam in a chronic mild stress model
Filatova and colleagues (2017) in Behavioural Neurology reported that Selank enhanced the effect of diazepam in reducing anxiety-like behaviour in rats under unpredictable chronic mild stress. The combination design asks whether the peptide shifts the response to a well-characterized GABA-A receptor positive modulator in a stress paradigm. The finding is model-specific and is not guidance for any use outside controlled animal research.
Clinical literature (published findings only)
A smaller body of clinical literature exists, including Medvedev and colleagues (2014) in Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova (PMID: 25176261). Those papers are part of the published record. They are not a substitute for large, independently replicated trials; the core evidence base summarized here remains animal and molecular work.
Limits of the evidence
Read the Selank literature with a few cautions in mind:
- Mostly rodent models. The mechanistic findings above come from rats. Changes in BDNF, gene expression or behaviour in those models do not show what happens in other species or settings.
- A concentrated research community. Much of the published work comes from a small number of connected groups. Independent replication from other laboratories is limited.
- mRNA and content are not whole pathways. Gene-expression and BDNF-content studies measure selected molecular endpoints. They do not by themselves prove a full mechanism.
- Short or defined time windows. Many studies sample at hours to days after administration under specific stress or pharmacological conditions.
None of the research above is evidence of effects in people for product or treatment purposes. These are published preclinical findings, reported here as such.
Research applications
In the published literature, Selank has been used as a tool to study:
- BDNF expression and content in rodent hippocampus and prefrontal cortex
- Expression of genes linked to GABAergic neurotransmission
- Anxiety-like behaviour and memory endpoints in stress and ethanol models
- Structure–activity questions about tuftsin analogues and peptidase-resistant C-terminal extensions such as PGP
Characterization and handling
As with any short peptide, results depend on material quality:
- Identity: confirm the molecular weight by mass spectrometry against the expected mass for Thr-Lys-Pro-Arg-Pro-Gly-Pro.
- Purity: HPLC purity on the batch certificate of analysis (see our guide to reading a peptide COA).
- Storage: keep lyophilized material cold, dry and protected from light, and avoid repeated freeze–thaw cycles once it is in solution (see how to store research peptides).
- Controls: where the question involves the C-terminal extension, consider a PGP-only comparison, as related neuropeptide studies have done for Semax.
Frequently asked questions
What is Selank made of? It is a heptapeptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro: the tuftsin tetrapeptide plus a C-terminal Pro-Gly-Pro extension.
Is Selank the same as tuftsin? No. It is a synthetic analogue that keeps the tuftsin core and adds Pro-Gly-Pro. Native tuftsin is the tetrapeptide alone.
What has Selank research mainly measured? In the studies summarized here, BDNF expression or content in rat brain, GABAergic gene expression, and behavioural endpoints in stress, anxiety and ethanol models.
How does Selank relate to Semax? Both are research heptapeptides that use a Pro-Gly-Pro C-terminal extension. Semax is built from an ACTH fragment; Selank is built from tuftsin. See our Semax research overview.
Related reading
- Semax Research: The ACTH(4-10) Analogue and Its Published Findings
- Peptide COA Explained: How to Read a Certificate of Analysis
- How to Store Research Peptides
All materials discussed are for laboratory research use only.
References
- Inozemtseva LS, Karpenko EA, Dolotov OV, Levitskaya NG, Kamensky AA, Andreeva LA, Grivennikov IA. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Doklady Biological Sciences. 2008;421:241-243. PMID: 18841804.
- Kolik LG, Nadorova AV, Antipova TA, Kruglov SV, Kudrin VS, Durnev AD. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats. Bulletin of Experimental Biology and Medicine. 2019;167(5):641-644. PMID: 31625062. doi:10.1007/s10517-019-04588-9.
- Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein & Peptide Letters. 2018. PMID: 30255741.
- Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, Slominsky P. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology. 2016;7:31. doi:10.3389/fphar.2016.00031.
- Filatova E, et al. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behavioural Neurology. 2017;2017:5091027. PMID: 28280289. doi:10.1155/2017/5091027.
- Medvedev VE, et al. [Clinical comparison involving Selank]. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 2014. PMID: 25176261. (Published clinical literature; cited for completeness only.)